FDA
-
-
-
-
-
-
-
Cartesian Therapeutics names CEO Carsten Brunn as board chairman
-
-
-
-
-
-
-
Cartesian Therapeutics Announces New Employment Inducement Grants
-
-
-
-
-
-
-
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) PT Lowered to $41 at Needham
-
-
-
-
-
-
-
Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
-
-
-
-
-
-
-
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

